GCP
IMUC

GSA Capital Partners’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

GSA Capital Partners’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,595
Closed -$57K – 2110
2014
Q3 		$57K Buy
1,595
+1,257
+372% +$48.4K ﹤0.01% 1654
2014
Q2 		$15K Buy
+338
New +$16.3K ﹤0.01% 1770

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GSA Capital Partners's IMUC Position: Q4 2014 in Review

GSA Capital Partners sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2014, closing a stake of 1,595 shares — an estimated $57K sold.

GSA Capital Partners first reported a position in IMUC in Q2 2014 and held it in 2 quarters. The position peaked at $57K in Q3 2014. 31 funds tracked by Wall St. Rank hold IMUC as of Q4 2014.

  • GSA Capital Partners reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2014 after selling out during the quarter.
  • GSA Capital Partners sold 1,595 ImmunoCellular Therapeutics, Ltd. shares in Q4 2014, an estimated $57K.
  • GSA Capital Partners first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2014 and held it in 2 quarters.
  • GSA Capital Partners's ImmunoCellular Therapeutics, Ltd. position peaked at $57K in Q3 2014.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2014.

Based on GSA Capital Partners's 13F filing for Q4 2014, filed 5 Feb 2015.